Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Cowen & Co. Downgrades Fate Therapeutics to Market Perform

Cowen & Co. analyst Tyler Van Buren downgrades Fate Therapeutics (NASDAQ:FATE) from Outperform to Market Perform.

byBenzinga Newsdesk

January 6, 2023

1 minute read

Cowen & Co. analyst Tyler Van Buren downgrades Fate Therapeutics (NASDAQ:FATE) from Outperform to Market Perform.

Elon Musk’s Twitter Under White House Scanner: ‘We’re All Keeping A Close Eye On This’

By Shivdeep Dhaliwal

Today, 8:01 AM

Elon Musk-led Twitter is under the scanner of the Joe Biden administration when it comes to misinformation on…

AAPL

Why Comcast Shares Are Falling

By Randy Elias

Today, 8:01 AM

Comcast Corporation (NASDAQ: CMCSA) shares are trading lower after Wells Fargo maintained an Underweight rating on the stock and lowered its price target from $49 to $46.

CMCSA

Chembio Diagnostics Q2 EPS $(0.45) Misses $(0.27) Estimate, Sales $6.46M Miss $8.53M Estimate

By Benzinga Newsdesk

Today, 8:01 AM

Chembio Diagnostics (NASDAQ:CEMI) reported quarterly losses of $(0.45) per share which missed the analyst consensus estimate of $(0.27) by 66.67 percent. This is a 7.14 percent decrease over losses of $(0.42) per share

CEMI